TLPH NASDAQ
Talphera, Inc.
1W: -4.2%
1M: -5.8%
3M: -4.2%
YTD: -2.6%
1Y: +21.1%
3Y: +101.8%
5Y: -94.7%
$1.13
+0.01 (+0.89%)
Weekly Expected Move ±3.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
19 relationships19
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-03-30
Earliest Filing
2025-09-10
Latest Filing
partner: 10
investor: 3
acquirer: 3
target: 1
supplier: 1
customer: 1
Counterparties (Filed by TLPH)
19 relationshipsCompanies named in TLPH's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| CorMedix Inc. | CRMD | investor | Purchaser of common stock and pre-funded warrants in a private placement; granted board seat and right of first negotiat | 2025-09-10 | View |
| XOMA (US) LLC | — | investor | Purchased receivables from Talphera, Inc. for $8 million | 2024-01-18 | View |
| Vertical Pharmaceuticals, LLC | — | partner | Original counterparty in the Asset Purchase Agreement for DSUVIA® products | 2024-01-18 | View |
| Alora Pharmaceuticals, LLC | — | acquirer | Parent company of Vertical Pharmaceuticals, LLC which acquired DSUVIA assets from AcelRx Pharmaceuticals, Inc. | 2023-04-07 | View |
| Vertical Pharmaceuticals, LLC | — | acquirer | Wholly owned subsidiary of Alora Pharmaceuticals, LLC that acquired DSUVIA assets from AcelRx Pharmaceuticals, Inc. | 2023-04-07 | View |
| Vertical Pharmaceuticals, LLC | — | acquirer | Acquired certain assets and liabilities related to sufentanil sublingual tablet products from AcelRx | 2023-03-16 | View |
| Alora Pharmaceuticals, LLC | — | partner | Parent company of Vertical Pharmaceuticals, LLC, the buyer in the asset purchase agreement | 2023-03-16 | View |
| Laboratoire Aguettant | — | partner | Existing partner with AcelRx for European commercialization of DZUVEO and supplier of certain products | 2023-03-16 | View |
| Catalent Pharma Solutions, LCC | — | partner | Counterparty to terminated Site Readiness Agreement and commercial supply agreement with AcelRx | 2023-03-16 | View |
| Lincoln Park Capital Fund, LLC | — | investor | Purchased 3,000 shares of Series A Preferred Stock and warrants for $300,000 in a private placement transaction. | 2022-08-04 | View |
| Lowell Therapeutics, Inc. | — | target | Target company acquired via merger agreement | 2022-01-12 | View |
| Computershare Inc. | — | partner | Rights Agent for Contingent Value Rights Agreement | 2022-01-12 | View |
| Computershare Trust Company, N.A. | — | partner | Wholly-owned subsidiary of Computershare Inc. acting as Rights Agent | 2022-01-12 | View |
| Laboratoire Aguettant | — | partner | Exclusive license and commercialization partner for DZUVEO in Europe and PFS products in the US. | 2021-07-14 | View |
| Catalent Pharma Solutions, LLC | — | supplier | Agreement for processing and packaging of DSUVIA single dose applicator | 2021-04-27 | View |
| Weichert Workforce Mobility, Inc. | — | partner | Successor in interest to The MI Group, Inc., entered into a new sublease agreement with the Company. | 2021-03-30 | View |
| The MI Group, Inc. | — | partner | Predecessor to Weichert Workforce Mobility, Inc., referenced as the original sublessor of the premises. | 2021-03-30 | View |
| Metropolitan Life Insurance Company | — | partner | Entered into a Lease Termination Agreement with the Company to terminate the existing lease. | 2021-03-30 | View |
| Genomic Health, Inc. | — | customer | Entered into a Sublease Termination Agreement with the Company to terminate its existing sublease. | 2021-03-30 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-06-23 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-23 | Earnings Release; Exhibits | View | |
| 2026-03-16 | Unregistered Sales of Equity Securities | View | |
| 2026-03-13 | Notice of Delisting or Transfer | View | |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-24 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-10-22 | Unregistered Sales of Equity Securities; Other Events | View | |
| 2025-10-16 | Departure/Election of Directors; Appointment of Officers | View | |
| 2025-09-10 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-05 | Notice of Delisting or Transfer | View | |
| 2025-05-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-04-02 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-03-31 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-12-11 | Notice of Delisting or Transfer | View | |
| 2024-11-29 | Notice of Delisting or Transfer | View | |
| 2024-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-01 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR